Table 4. Multivariate Model for Progression-Free Survival in the Matched Population of Patients With Enteropancreatic Neuroendocrine Tumors Who Received Upfront PRRT or Upfront Chemotherapy or Targeted Therapy.
| Covariate | HR (95% CI) | P value | Interaction between PRRT and other covariates | |
|---|---|---|---|---|
| aHR (95% CI) | P value | |||
| Treatment group | ||||
| Chemotherapy or targeted therapy | 1 [Reference] | <.001 | NA | NA |
| PRRT | 0.37 (0.26-0.51) | NA | NA | |
| Functioning tumors | ||||
| No | 1 [Reference] | .67 | 0.29 (0.16-0.56) | <.001 |
| Yes | 0.91 (0.66-1.31) | 0.39 (0.27-0.57) | <.001 | |
| Primary site | ||||
| Pancreas | 1 [Reference] | .12 | 0.41 (0.24-0.61) | <.001 |
| Intestine | 0.97 (0.71-1.34) | 0.19 (0.11-0.43) | <.001 | |
| Grade according to 2019 WHO classification20 | ||||
| 1 | 1 [Reference] | NA | 0.21 (0.12-0.34) | <.001 |
| 2 | 0.95 (0.67-1.36) | .84 | 0.52 (0.29-0.73) | <.001 |
| 3 | 2.64 (1.19-6.27) | .01 | 0.31 (0.12-1.37) | .13 |
| Ki-67 proliferation index >10% | ||||
| No | 1 [Reference] | .47 | 0.71 (0.18-0.37) | <.001 |
| Yes | 0.86 (0.56-1.31) | 0.73 (0.29-1.43) | .31 | |
Abbreviations: aHR, adjusted hazard ratio; HR, hazard ratio; NA, not applicable; PRRT, peptide receptor radionuclide therapy; WHO, World Health Organization.